Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.

India, Oct. 6 -- The global demand for Vitamin D3 is being supported by rising health awareness, increasing nutritional ...

A biotech company that makes supplements from whisky by-products has been given £2.5m by the Scottish National Investment ...

At the industry's top events, pharma professionals can dive into these issues and more through educational sessions, networking events and keynote presentations from industry leaders. Here's a look at ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...

ArriVent BioPharma Inc.’s stocks have been trading down by -57.66 percent amid heightened concern over its latest clinical ...

Dutch haul comes despite European drugmakers and investors warning the region is losing ground.

A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.